Researchers discover pathway that makes glioblastoma cells vulnerable to treatment

For patients facing glioblastoma, the deadliest form of brain cancer, survival has remained tragically short. Even with the best treatments available, most people diagnosed with this cancer live only about 14 months. That number used to be even lower — less than one year just a decade ago. But now, a team of researchers from Virginia thinks they may have found a new way to attack these tumors. Their discovery centers on a protein called TRNAU1AP, which helps cancer cells survive and multiply. Scientists believe blocking this protein could make the cancer vulnerable to treatment for the first time.

The research came from Virginia Commonwealth University, working with the VCU Massey Comprehensive Cancer Center and the University of Texas MD Anderson Cancer Center. Led by Suyun Huang, a professor and cancer researcher at VCU, the team studied glioblastoma tumor samples and found that TRNAU1AP forms tiny clusters inside cells. These clusters help produce other proteins called selenoproteins, which use a mineral called selenium to shield cells from damage. In simple terms, TRNAU1AP acts like a factory supervisor, keeping the cancer cells running smoothly and helping them resist treatment.

The researchers also discovered that another protein, called IGF2BP3, works to keep TRNAU1AP levels high inside tumor cells. Patients whose tumors contained higher amounts of TRNAU1AP tended to have worse outcomes. This suggested to the team that if they could interrupt the relationship between IGF2BP3 and TRNAU1AP, they might be able to weaken the cancer.

"We think we could potentially target it to kill this tumor," Huang said. "If we have a way to inhibit these proteins, it could open up new pathways to treat this deadly disease."

The findings, published in the journal Neuro-Oncology, represent years of work studying how glioblastoma cells resist therapy. Glioblastoma is especially hard to treat because it contains cancer stem cells that keep the tumor growing even when other parts are destroyed. These stem cells act like the roots of a weed — cut the leaves, and the roots just grow more.

Looking ahead, Huang wants to develop drugs that can cross the blood-brain barrier, the protective layer that shields the brain from most medications. A small molecule that could slip through this barrier and block the IGF2BP3 protein might reduce the stability of TRNAU1AP and slow tumor growth. The team is now planning further studies to test this approach.

The road from laboratory discovery to a treatment that helps patients is long and uncertain. But for a disease that has seen so few advances over so many years, this finding offers real reason for hope.